“Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years”, J of Skin, vol. 9, no. 2, p. s573, Mar. 2025, doi: 10.25251/skin.10.supp.573.